Low to medium potent topical corticosteroids

DRUG2 trials

Conditions

Neurodermatitis

Phase 3

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)

CompletedNCT04183335

SanofiNeurodermatitis

Start: 2019-12-12End: 2022-02-03Updated: 2025-09-17

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)

CompletedNCT04202679

SanofiNeurodermatitis

Start: 2020-01-16End: 2021-11-22Updated: 2025-09-17

Dermatology and Therapy2026-04-01

Dupilumab Improves Daily Symptom Burden in Adult Patients with Prurigo Nodularis: Post Hoc Analysis from LIBERTY PN-PRIME and PRIME2 Studies.

2026-03-02

Dupilumab Reduces Pruritus in Clinically Distinct Dermatologic Diseases: Data from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria.

2025-11-22

Efficacy and Safety of Dupilumab in Adults with Prurigo Nodularis with or Without Atopic Comorbidities: A Subgroup Analysis from Two Randomized Phase III Clinical Trials.

2025-11-11

635 - Dupilumab is efficacious in patients with prurigo nodularis regardless of baseline lesion severity: pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2)

British Journal of Dermatology2024-08-011 citations

Worst Itch Numeric Rating Scale for Prurigo Nodularis: A Secondary Analysis of 2 Randomized Clinical Trials.

2024-08-011 citations

694 - Dupilumab improves itch and skin lesions in North American patients with prurigo nodularis: a subset analysis of the pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2)

British Journal of Dermatology2024-08-01

718 - Dupilumab reduces the number of lesions in adult patients with prurigo nodularis presenting with multiple lesion morphologies: pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2)

British Journal of Dermatology2024-08-01

P082 Dupilumab is efficacious in patients above and below 60 years old with prurigo nodularis: pooled results from two phase III trials (LIBERTY-PN PRIME and PRIME2)

British Journal of Dermatology2024-06-28

Responder analysis using clinically meaningful thresholds: Post hoc analyses from randomized dupilumab clinical trials in patients with prurigo nodularis

Journal of the European Academy of Dermatology and Venereology2024-05-246 citations

Validation of a scoring algorithm for the clinician‐reported outcome tool ‘prurigo activity and severity (<scp>PAS</scp>)’ based on clinical studies of dupilumab in adults with prurigo Nodularis

Journal of the European Academy of Dermatology and Venereology2024-04-023 citations

Estimating meaningful change thresholds for Skin Pain‐Numeric Rating Scale, Sleep‐Numeric Rating Scale and Dermatology Life Quality Index in patients with prurigo nodularis

Journal of the European Academy of Dermatology and Venereology2024-02-086 citations

510 - Dupilumab is efficacious in patients with prurigo nodularis regardless of stable use of topical corticosteroids and topical calcineurin inhibitors: pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2)

British Journal of Dermatology2024-02-011 citations

506 - Dupilumab is efficacious in patients with prurigo nodularis regardless of history of atopic comorbidities: pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2)

British Journal of Dermatology2024-02-01

P71 Dupilumab improves patient-reported itch and other signs and symptoms of disease in adults with prurigo nodularis (LIBERTY-PN PRIME and PRIME2)

British Journal of Dermatology2023-06-01

Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials

Nature Medicine2023-05-01193 citations

Maintenance of response to dupilumab in prurigo nodularis: A retrospective cohort study

JAAD International2023-02-247 citations

344 Dupilumab significantly improves itch and skin lesions in patients with prurigo nodularis: pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2)

British Journal of Dermatology2023-01-254 citations

341 Dupilumab improves itch and skin lesions in adults with prurigo nodularis regardless of prior use of immunosuppressants or phototherapy: post-hoc results from PRIME and PRIME2 clinical trials

British Journal of Dermatology2023-01-25

343 Dupilumab efficacy on itch and skin lesions in adult patients with prurigo nodularis may be observed concurrently or independently over 24 weeks: results from two phase 3 trials

British Journal of Dermatology2023-01-25

1 more papers not shown

Low to medium potent topical corticosteroids

Sponsors

Conditions

Phase 3

Related Papers